The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy

The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy: A Randomized Clinical Trial And Its Standard Technology Promotion Research

1. To determine the influencing factors of modified electroconvulsive therapy (MECT);
2. To determine the influencing factors and reversibility of the cognitive impairment caused by MECT;
3. To determine the duration of efficacy of MECT and its affecting factors.

Inclusion Criteria:

• Aged over 18 years (when informed consent was got), male or female
• Meet International Classification of Diseases-10(ICD-10) diagnostic criteria for depression
• Scored 18 or above on the HAM-D Scale which included 17 items
• Clinical Global Impression(CGI)-severity score ≥ 4
• Provided written informed consent

Exclusion Criteria:

• Any depressive disorders not due to major depressive disorder
• Meet other diagnosis criteria in Diagnostic and Statistical Manual of Mental Disorders-IV-Test Revision(DSM-IV-TR) Axis I
• With a history of acute or chronic renal failure, liver cirrhosis or active hepatopathy
• With clinically significant abnormal results of laboratory test, which are considered to have impact on treatment efficacy and the safety of participants
• With a history of severe or unstable physical disease including nervous system disease and myocardial infarction
• Undergoing alcoholism or alcohol (or substance) abuse during 30 days or 6 months before the trial
• With no response to previous ECT treatment
• Received transcranial magnetic stimulation treatment in the last 6 months
• Allergic to propofol, etomidate and succinylcholine chloride
• During pregnancy or lactation
• With a history of stroke in the last month
• Enrolled in any other clinical trial 30 days prior to the baseline